St. Jude Medical slides on negative results from heart implant trial

Thu, 10/25/2012 - 1:09pm
Mass Device

St. Jude Medical shares are down 4% today after clinical trial results show no significant benefit from its Amplatzer heart implant.

St. Jude Medical

St. Jude Medical (NYSE:STJ) shares lost 4% today after studies of its Amplatzer heart implant failed to significantly reduce cryptogenic stroke compared with standard treatment with drugs.

The device is designed to treat a condition called patent foramen ovale, in which a naturally-occurring hole in the heart fails to close after birth, potentially allowing blood clots to travel from 1 side of the hart to the other and then to the brain, causing a stroke.

The St. Paul-based medical device company sponsored the larger study, of 980 patients, which tracked them at intervals of 1 month, 6 months, 12 months, 18 months, 24 months and then annually until 25 strokes or deaths occurred. It showed that 9 patients in the Amplatzer arm suffered non-fatal strokes, compared with 16 for the drug treatment cohort. There were no deaths or fatal strokes in either arm.


Share this Story

You may login with either your assigned username or your e-mail address.
The password field is case sensitive.